Dostarlimab, an anti–PD-1 monoclonal antibody marketed by GSK (LSE: GSK) under the brand name Jemperli, has shown impressive results in mismatch repair–deficient stage II or III rectal adenocarcinoma.
Findings from a prospective Phase II study were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine.
During this research, dostarlimab was administered every three weeks for six months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze